Click to watch the live stream and join the conversation. #PhRMA16

0 SHARES

0

0

0

1

0 SHARES

0

0

0

1

Maryland

Research In Your Backyard

Number Of Clinical Trials : 1,405


In the development of new medicines, clinical trials are conducted to prove therapeutic safety and effectiveness and compile the evidence needed for the Food and Drug Administration (FDA) to approve treatments.

"Because of its strong research infrastructure, which includes the National Institutes of Health (NIH), Johns Hopkins University and the University of Maryland, Maryland is competitive with some much larger states in its number of clinical trials of new medicines. The nation’s biopharmaceutical research companies have conducted nearly 3,500 new drug tests in the state since 1999 in collaboration with these widely respected institutions and many others."

Douglas A. Doerfler, Vice Chairman, MdBio Division, Tech Council of Maryland



  • 25,291

    Number Of Clinical Trial Participants


  • $221.8
    million

    Amount Invested In
    Clinical Trials


  • $526.7
    million

    Total Economic Impact Of Clinical Trial Investments

It takes about 10 years to develop one new medicine. Clinical trials are the most time- and resource-intensive part of the research and development (R&D) process for a new medicine, and biopharmaceutical companies support and conduct the lion’s share of this work. Yet without clinical trials, new medicines could not be approved and made available to the patients who need them.

Beyond the profound value that biopharmaceutical industry R&D brings patients in the form of new treatments and potential cures for society’s most devastating and costly diseases are the significant economic impacts resulting from clinical trials conducted in communities across the country.*



Learn more about Research in Your Backyard, a series of reports that highlight the importance of clinical trials to patients' health, as well as the contributions to local economies.

* The data presented here focuses solely on investments at clinical trial sites, which are only a portion of the full economic impact of R&D supported by the biopharmaceutical industry. In addition to excluding pre-discovery and preclinical research and other activities related to trial design, management coordination, and analysis, as well as any other activities occurring beyond the operations at the site level, were beyond the scope of this research. The report also excludes the large nationwide economic impact associated with non-R&D activities, including manufacturing and distribution.

connect with PhRMA...

Make your voice heard. Join the important discussion on the value and economic impact of new medicines.


connect with PhRMA...

Make your voice heard. Join the important discussion on the value and economic impact of new medicines.


  • +68K

    Followers

  • +57K

    Followers

  • 366

    Followers

  • 3343

    Subscribers